TissueGene to Highlight Invossa™, the World's First Cell-Mediated Gene Therapy for Degenerative Osteoarthritis, at JP Morgan Healthcare Conference

ROCKVILLE, Md., Jan. 9, 2017 /PRNewswire/ -- TissueGene, Inc. ("TissueGene"), a Maryland-based regenerative medicine company, announced today that CEO Woosok Lee will present at the 35^th Annual JP Morgan Healthcare conference on Wednesday, January 11^th at 2:30PM PT at the Westin St. Francis in San Francisco (Victor's, 32^nd Floor).

Mr. Lee will introduce TissueGene's Invossa™, the world's first cell and gene therapy for degenerative arthritis.  Invossa™ is a first-in-class osteoarthritis drug designed to conveniently and effectively treat osteoarthritis of the knee through a single intra-articular injection.  Clinical trials completed in Korea and on-going trials in the US have demonstrated pain relief, increased mobility, and improvements in joint structure – offering substantial convenience and therapeutic benefits for osteoarthritis patients, while delaying their need for surgery.

Mr. Lee will speak at the conference to present Invossa™'s innovative cell and gene technology and the promising efficacy results from the US and Korean clinical trials. He will also discuss the global market strategy for Invossa, including the recent $440M partnership deal with Mitsubishi Tanabe for Invossa™ in the Japanese market. 

"We are honored to present the world's first potential DMOAD for knee osteoarthritis at the JP Morgan Healthcare conference," Mr. Lee stated.

Recently, TissueGene's licensee, Kolon Life Sciences, filed for a biologics license application (BLA) for Invossa™ with the Korea Ministry of Food and Drug Safety (MFDS).  Additionally, TissueGene's upcoming US Phase 3 clinical trial will aim for approval for Invossa™ from the US Food and Drug Administration (FDA) as the first disease-modifying osteoarthritis drug (DMOAD).

TissueGene, Inc. 
TissueGene, Inc., is a Maryland-based regenerative medicine company specializing in cell and gene therapy. TissueGene's lead product is Invossa™, an allogeneic, cell-mediated gene therapy for osteoarthritis of the knee that has completed Phase II clinical trials in the US.  TissueGene has recently reached an agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment (SPA) for a Phase 3 clinical trial for Invossa™. Information can be found at the NIH registry, www.clinicaltrials.gov.  For additional information about TissueGene, Inc., please visit www.tissuegene.com.

SOURCE TissueGene, Inc.

Related Links

http://www.tissuegene.com